Cancer cell - PDFSEARCH.IO - Document Search Engine

Cancer cell
Results: 3981

#	Item
21	ASX ANNOUNCEMENT 14 October 2015 Cynata to Investigate Cell Therapy for Cancer in Major New Collaboration Add to Reading List Source URL: cynata.com - Date: 2016-03-08 18:52:12
22	A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R, Add to Reading List Source URL: s3.amazonaws.com - Date: 2014-09-25 16:14:56
23	NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3) Add to Reading List Source URL: posters.omed.s3.amazonaws.com - Date: 2015-12-11 14:21:05
24	Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in Add to Reading List Source URL: posters.omed.s3.amazonaws.com - Date: 2015-06-12 10:36:45
25	Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain Add to Reading List Source URL: posters.omed.s3.amazonaws.com - Date: 2015-11-04 11:34:18
26	Phase 1b Trial of Tarextumab (OMP 59R5) (anti-Notch 2/3 antibody) in Combination with Etoposide and Cisplatin (EP) in Patients (pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (ED-SCLC): PINNACLE Study M Cathe Add to Reading List Source URL: s3.amazonaws.com - Date: 2014-09-25 16:16:58
27	NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3) Add to Reading List Source URL: posters.omed.s3.amazonaws.com - Date: 2016-02-21 23:46:50
28	A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years) Add to Reading List Source URL: posters.omed.s3.amazonaws.com - Date: 2016-01-22 10:42:40
29	A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM Add to Reading List Source URL: s3.amazonaws.com - Date: 2014-09-25 16:14:56
30	Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency Wan-Ching Yen, Marcus M. Fischer, Gretchen Argast, Breanna Wallace, Min Wan Add to Reading List Source URL: posters.omed.s3.amazonaws.com - Date: 2015-11-04 11:34:26